Akorn Agrees to Purchase Hi-Tech Pharmacal for $640 Million

Akorn Inc., a maker of generic eye-care products, agreed to buy Hi-Tech Pharmacal Co. for $640 million in cash to expand into areas including cold and cough treatments.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.